MedImmune Bolsters Oncology Pipeline Under Agreement With Infinity
This article was originally published in The Pink Sheet Daily
Executive Summary
Deal for development of two candidates could be worth up to half a billion dollars.
You may also be interested in...
Infinity Regains Rights To Its Lead Program
Biotech pays nothing upfront to regain the Phase III HSP90 inhibitor, which is still on track in multiple clinical trials.
Infinity Regains Rights To Its Lead Program
Biotech pays nothing upfront to regain the Phase III HSP90 inhibitor, which is still on track in multiple clinical trials.
With Innovative Purdue Deal, Infinity Finds Shelter From The Storm
In exchange for ex-U.S. rights to the bulk of its early-stage oncology pipeline, Infinity has secured a cash runway into 2013.